VTVT

15.5105.20%
AM

Anne Michelle Phillips

Independent Director

Dr. Anne Michelle Phillips, M. D. FRCPC, is an Independent Director of vTv Therapeutics Inc. from February 2024. She serves as an Independent Director at Carmot Therapeutics, Inc. from September, 2022. She is Director of Sagimet Biosciences Inc. from August 1, 2024. She serves as an Independent Non-Executive Director at Barinthus Biotherapeutics plc (formerly known as Vaccitech plc) and served as Non-Executive Director since February 17, 2021 until March 31, 2021. She had been an Independent Director of AMAG Pharmaceuticals, Inc. since April 12, 2019 until November 16, 2020. Dr. Phillips served as a Senior Vice President of U. S. Clinical, Medical and Regulatory Affairs at Novo Nordisk A/S since March 1, 2013. Dr. Phillips served as Member of Supervisory Board at AMAG Austria Metall AG since April 12, 2019. Dr. Phillips served as a Senior Vice President of Clinical Medical & Regulatory Affairs at Novo Nordisk, Inc. until 2022, where she has overseen more than a dozen FDA drug approvals. She served as Member of the U. S. Executive Team of Novo Nordisk, Inc. since January 3, 2011 until March 13, 2017. She served as a Member of the Senior Management Board of Novo Nordisk since March 1, 2013. She served as Head of the Infectious Diseases Program and Deputy Physician-in-Chief at Wellesley Central Hospital/St. Michael's Hospital in Toronto. She served as Corporate Vice President of U. S. Clinical, Medical and Regulatory Affairs at Novo Nordisk until March 2013. Dr. Phillips served as Vice President of Clinical Development Medical & Regulatory Affairs for North America at Novo Nordisk since January 3, 2011. Dr. Phillips has extensive biopharmaceutical product development experience. She has medical, research and regulatory experience. She worked within its Research and Development organization at GlaxoSmithKline since 1998. She served as a Medical Advisor and advanced into leadership roles and as Vice President of Medicine Development Leader within GSK's Oncology R&D organization. From 2005 to 2009, she Headed a global team which supported Phase II-IV activities in the metabolic clinical area and provided leadership into development of all GSK metabolic and cardiovascular molecules and assets. She had been an Independent Director of Trevena, Inc. since 2014 until November 05, 2024. She is a Fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Phillips received her medical degree from the University of Toronto B. Sc. in Zoology from the University of Western Ontario.

Positions